Featured Research

from universities, journals, and other organizations

Blood Test May Be Superior To CT Scans In Predicting Survival In Some Ovarian Cancer Patients

Date:
September 14, 2004
Source:
American Society Of Clinical Oncology
Summary:
A new study shows that the CA125 blood test, which measures the level of protein produced by ovarian cancer cells in the blood, may be superior to standard imaging techniques like CT scans in predicting survival in patients with recurrent ovarian cancer.

Alexandria, VA -- A new study shows that the CA125 blood test, which measures the level of protein produced by ovarian cancer cells in the blood, may be superior to standard imaging techniques like CT scans in predicting survival in patients with recurrent ovarian cancer. The study, to be published online September 13 in the Journal of Clinical Oncology, is the first to compare the two procedures with respect to survival.

Related Articles


"This is good news for patients – our study indicates that selected patients can be safely monitored by blood tests alone and thus avoid costly and time consuming CT scans," said Bo Gronlund, MD, lead author and head of the CODOVA database at the Department of Oncology at Rigshospitalet, the Copenhagen University Hospital.

CT scans and other imaging techniques are often used in patients with recurrent cancer to assess whether the patient is responding to treatment. RECIST, the standard criteria for analyzing CT scans and ultrasonography, assesses treatment response by measuring the growth or shrinkage of the tumor.

However, unlike other solid tumors, ovarian cancer spreads diffusely through the abdomen, making tumor tissue much more difficult to detect through CT scans. As a result, response cannot always be measured by RECIST criteria.

Researchers hypothesized that the CA125 blood test might be a better tool for observing tumor growth among patients whose cancer has returned than traditional imaging techniques. To compare the two procedures, they used the RECIST criteria and a set of criteria for the CA125 blood test, which assesses treatment response according to the level of CA125 protein present in the blood.

Using one of the world's largest database of patients with recurrent ovarian cancer, researchers retrospectively studied 131 patients receiving topotecan or paclitaxel-carboplatin as a second-line chemotherapy. Researchers found that the CA125 criteria were 2.6 times more accurate than RECIST in predicting survival, and concluded that in selected patients, tumor-marker guided response criteria like CA125 may be superior to imaging-based response criteria in predicting the outcome of second-line chemotherapy.

However, researchers noted that the study findings are only applicable to patients treated with topecan or paclitaxel-carboplatin, and pointed to the need for a randomized trial that includes additional chemotherapy agents or novel targeted therapies and that assesses CA125 and RECIST criteria in predicting both survival and quality of life.

An accompanying editorial by Professor Gordon J.S. Rustin of Mount Vernon Cancer Centre in Middlesex, UK underscored the importance of determining which response criteria is the more reliable method for predicting survival and clinical benefit.

"The CA125 response criteria has great potential value in clinical trials. Increased confidence in a CA125 response definition should lead to a cheaper, and in some cases, more accurate method for monitoring ovarian cancer therapy than standard radiographic criteria," he said.

###

"Should CA125 Response Criteria be Preferred to RECIST for prognostication during Second-Line Chemotherapy of Ovarian Carcinoma?" Bo Gronlund et al, Copenhagen University Hospital, Copenhagen, Denmark.

The Journal of Clinical Oncology is the semi-monthly peer-reviewed journal of the American Society of Clinical Oncology (ASCO), the world's leading professional society representing physicians who treat people with cancer.


Story Source:

The above story is based on materials provided by American Society Of Clinical Oncology. Note: Materials may be edited for content and length.


Cite This Page:

American Society Of Clinical Oncology. "Blood Test May Be Superior To CT Scans In Predicting Survival In Some Ovarian Cancer Patients." ScienceDaily. ScienceDaily, 14 September 2004. <www.sciencedaily.com/releases/2004/09/040913084520.htm>.
American Society Of Clinical Oncology. (2004, September 14). Blood Test May Be Superior To CT Scans In Predicting Survival In Some Ovarian Cancer Patients. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2004/09/040913084520.htm
American Society Of Clinical Oncology. "Blood Test May Be Superior To CT Scans In Predicting Survival In Some Ovarian Cancer Patients." ScienceDaily. www.sciencedaily.com/releases/2004/09/040913084520.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins